GMOV - ETF AI Analysis
Top Page
GMO US Value ETF (GMOV)
GMOV, the GMO US Value ETF, appears to be a solid, quality-focused fund, supported by strong holdings like Microsoft and Merck, which bring robust financial performance, growth in areas like cloud, AI, and healthcare, and generally positive long-term outlooks. Verizon and Qualcomm also add to the fund’s strength with attractive valuations, solid cash flows, and favorable earnings trends, while some financial names such as JPMorgan and Bank of America face cash flow and leverage challenges that slightly weigh on the overall picture. The main risk factor is the fund’s exposure to large, established companies in sectors like tech and financials, where high valuations and debt levels could increase sensitivity to economic or market downturns.
GMOV vs. SPDR S&P 500 ETF (SPY)
- AUM
- 100.47M
- Region
- North America
- Expense Ratio
- 0.50%
- Beta
- 0.67
- Issuer
- GMO
- Inception Date
- Oct 28, 2024
- Dividend Yield
- 1.80%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
GMOV Summary
GMOV, the GMO US Value ETF, invests in a wide range of U.S. companies with a focus on stocks that appear cheap compared with their business strength. It does not track a specific index, but follows a value theme across the total U.S. market, including sectors like financials, health care, energy, and technology. Well-known holdings include Microsoft and Meta Platforms, along with major names in banking and pharmaceuticals. Someone might invest in GMOV for broad diversification with an emphasis on potentially undervalued companies. A key risk is that value stocks can stay out of favor for long periods, and the ETF’s price can go up and down with the overall market.
How much will it cost me?
GMOV has an expense ratio of 0.50%, which means you’ll pay about $5 per year for every $1,000 invested. This cost is higher than the average ETF because GMOV is actively managed, with professionals selecting value-focused U.S. stocks rather than simply tracking a broad market index.
What would affect this ETF?
GMOV could benefit if value stocks come back into favor, especially in U.S. financials, health care, and energy, and if large holdings like Microsoft, Meta, and Exxon Mobil continue to perform well in a stable or growing economy. On the downside, rising interest rates, weaker U.S. growth, or sector-specific issues in banks, drug companies, or big tech could hurt returns, and the fund’s active value approach may lag if investors prefer fast-growing or speculative stocks instead.
GMOV Top 10 Holdings
GMOV leans heavily into U.S. value names, with a clear tilt toward Big Tech and health care as its main engines. Microsoft has been steadily rising and looks like a key performance driver, while Meta’s mixed, recently lagging trade takes a bit of shine off the tech sleeve. In energy, Exxon Mobil has been powering ahead, giving the fund a strong cyclical boost. On the defensive side, Merck and Pfizer have been quietly climbing, helping offset weaker, more mixed showings from Verizon and Bristol-Myers. Overall, it’s a U.S.-centric value story with a few standout leaders pulling the wagon.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 MSFT | Microsoft | 7.20% | $7.23M | $3.87T | 8.06% | 79Outperform |
 META | Meta Platforms | 4.73% | $4.75M | $1.59T | 0.43% | 76Outperform |
 XOM | Exxon Mobil | 4.08% | $4.10M | $723.90B | 48.30% | 74Outperform |
 JPM | JPMorgan Chase | 2.80% | $2.81M | $898.41B | 13.86% | 72Outperform |
 MRK | Merck & Company | 2.50% | $2.51M | $356.93B | 79.30% | 80Outperform |
 PFE | Pfizer | 2.42% | $2.43M | $170.99B | 26.71% | 74Outperform |
 VZ | Verizon | 2.37% | $2.38M | $187.50B | 17.42% | 81Outperform |
 BMY | Bristol-Myers Squibb | 1.99% | $2.00M | $126.14B | 40.80% | 78Outperform |
 REGN | Regeneron | 2.08% | $2.09M | $100.68B | 48.20% | 78Outperform |
 PGR | Progressive | 1.72% | $1.73M | $132.74B | 12.04% | 78Outperform |
GMOV Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GMOV, the sentiment is Positive. The current price of 33.78 is above the 20-day moving average (MA) of 32.82, above the 50-day MA of 32.49, and above the 200-day MA of 30.24, indicating a bullish trend. The MACD of 0.31 indicates Negative momentum. The RSI at 68.77 is Neutral, neither overbought nor oversold. The STOCH value of 69.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GMOV.
GMOV Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| GMOV | $33.78 | $35.00(3.61% Upside) | $100.47M | 0.50% | 74Outperform |
 VFVA | $165.78 | $189.33(14.21% Upside) | $968.19M | 0.13% | 69Neutral |
 QVAL | $65.14 | $71.55(9.85% Upside) | $766.03M | 0.28% | 73Outperform |
 LSVD | $35.78 | $45.77(27.93% Upside) | $653.03M | 0.40% | 74Outperform |
 AIVL | $137.51 | $154.59(12.42% Upside) | $420.01M | 0.38% | 72Outperform |
 BUSA | $42.97 | $48.07(11.86% Upside) | $414.36M | 0.60% | 70Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GMOV | GMO US Value ETF | 33.78 | 8.29 | 32.50% | |
| VFVA | Vanguard U.S. Value Factor ETF | 165.78 | 43.63 | 35.72% | |
| QVAL | Alpha Architect U.S. Quantitative Value ETF | 65.14 | 19.78 | 43.61% | |
| LSVD | LSV Disciplined Value ETF | 35.78 | 7.30 | 25.62% | |
| AIVL | WisdomTree U.S. AI Enhanced Value Fund | 137.50 | 27.78 | 25.32% | |
| BUSA | Brandes U.S. Value ETF | 42.97 | 9.03 | 26.59% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.